Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fampridine sustained-release - Acorda Therapeutics

Drug Profile

Fampridine sustained-release - Acorda Therapeutics

Alternative Names: 4-AP - Acorda Therapeutics; Ampyra; BIIB 041; Dalfampridine ER; Dalfampridine extended-release; Dalfampridine-SR; EL 970; Fampridine ER; Fampridine extended-release; Fampridine-PR; Fampridine-SR; Fampyra; Neurelan

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Elan Drug Technologies
  • Developer Acorda Therapeutics; Biogen; John Hopkins University; Kessler Foundation; University of California at Los Angeles; University of Florida; University of Miami
  • Class Aminopyridines; Neuroprotectants; Small molecules
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries; Multiple sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Phase III Ataxia
  • Phase II Spinal cord injuries; Spinocerebellar degeneration; Transverse myelitis
  • Phase I/II Parkinson's disease
  • No development reported Cerebral palsy
  • Discontinued Neurological disorders

Most Recent Events

  • 10 Sep 2018 The US Court of Appeals for the Federal Circuit upholds District Court’s Decision to invalidate four dalfampridine patents
  • 17 Nov 2017 Acorda Therapeutics receives royalty monetisation with HealthCare Royalty Partners
  • 16 Oct 2017 Acorda Therapeutics completes a phase II trial in Spinal cord injuries in USA (PO) (NCT01621113)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top